Saturday, April 20, 2024

Roche Terminates Collaboration with Repare Therapeutics for ATR Inhibitor Camonsertib Development

Similar articles

Roche has concluded its global license and collaboration agreement with Repare Therapeutics Inc. concerning the development and commercialization of camonsertib (RP-3500). The rights to camonsertib, an oral small molecule inhibitor targeting Ataxia-Telangiectasia and Rad3-related (ATR) protein kinase, has reverted to Repare. The latter intends to proceed with the development of camonsertib across various tumor types.

Repare’s President and CEO, Lloyd M. Segal, expressed optimism about the future of camonsertib, stating, “Camonsertib is a valuable, high-potential precision oncology medicine that has achieved clinical proof-of-concept in multiple tumor types and genotypes both as monotherapy and in combination, as previously reported. We have been continuously running clinical trials for camonsertib since July 2020 and are excited to steward the progress of this promising therapy.”

A Multi-Billion Dollar Collaboration for Develop Promising Cancer Therapy Camonsertib

The collaboration between Roche and Repare, initiated in June 2022, entailed a significant upfront payment of $125 million and had the potential to reach up to $1.2 billion based on various milestones. Camonsertib, currently under development as both a monotherapy and in combination therapy, has exhibited promising safety and efficacy profiles across multiple solid tumors.

Roche’s Global Head of Pharma Partnering, James Sabry, MD, PhD, expressed enthusiasm about the emerging DNA damage response field and Roche’s commitment to personalized healthcare. He stated, “We are looking forward to collaboration with Repare Therapeutics to further develop camonsertib as a new potential treatment option for patients with significant unmet medical needs across a range of tumor types.”

Collaboration

Repare Hits Milestone for TAPISTRY Trial; Roche Initiates Morpheus Lung Trial Enrollment

Recent milestones include Repare’s achievement of a $40 million payment upon the initiation of the Phase II TAPISTRY trial, aimed at evaluating targeted therapies or immunotherapy in patients with specific oncogenic genomic alterations. Additionally, Roche enrolled the first patient in the Phase Ib/II Morpheus Lung trial, exploring multiple immunotherapy-based treatment combinations in metastatic non-small cell lung cancer patients.

However, just weeks later, Roche announced the termination of the agreement for camonsertib’s development and commercialization as of May 7, 2024, citing a review of its pipeline and evolving external factors. Repare emphasized its ongoing Phase I trial of camonsertib plus lunresertib in patients with advanced solid tumors, revealing promising overall response rates and RECIST objective responses, particularly in gynecologic tumors.

Repare reiterated its commitment to meet all obligations under the Roche agreement and expects existing financial resources to sustain planned operations into mid-2026. As the development of camonsertib progresses, further insights and data are anticipated, promising advancements in precision oncology and potential new treatment modalities for patients with challenging tumor types.

 

Resource: Pharmexec, February 14, 2024

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article